Skip to main content

Published locations for Nivolumab-ipilimumab combo has ‘robust’ clinical benefit in sorafenib-treated HCC patients

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Nivolumab-ipilimumab combo has ‘robust’ clinical benefit in sorafenib-treated HCC patients

User login

  • Reset your password
  • /content/nivolumab-ipilimumab-combo-has-robust-clinical-benefit-sorafenib-treated-hcc-patients
  • /fedprac/article/212354/oncology/nivolumab-ipilimumab-combo-has-robust-clinical-benefit-sorafenib
  • /internalmedicinenews/article/212354/oncology/nivolumab-ipilimumab-combo-has-robust-clinical-benefit
  • /oncologypractice/article/212354/oncology/nivolumab-ipilimumab-combo-has-robust-clinical-benefit
  • /fedprac/avaho/article/212354/oncology/nivolumab-ipilimumab-combo-has-robust-clinical-benefit
  • /hematology-oncology/article/212354/oncology/nivolumab-ipilimumab-combo-has-robust-clinical-benefit
  • /internalmedicine/article/212354/oncology/nivolumab-ipilimumab-combo-has-robust-clinical-benefit